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Abstract
Objectives To evaluate whole-body MRI (WB-MRI) param-
eters significantly associated with treatment response in mul-
tiple myeloma (MM).
Methods Twenty-one MM patients underwent WB-MRI at
diagnosis and after two cycles of chemotherapy. Scans
acquired at 3.0 T included T2, diffusion-weighted-
imaging (DWI) and mDixon pre- and post-contrast.
Twenty focal lesions (FLs) matched on DWI and post-
contrast mDixon were selected for each time point.
Estimated tumour volume (eTV), apparent diffusion coef-
ficient (ADC), enhancement ratio (ER) and signal fat frac-
tion (sFF) were derived. Clinical treatment response to
chemotherapy was assessed using conventional criteria.
Significance of temporal parameter change was assessed
by the paired t test and receiver operating characteristics/
area under the curve (AUC) analysis was performed.
Parameter repeatability was assessed by interclass
correlation (ICC) and Bland–Altman analysis of 10
healthy volunteers scanned at two time points.
Results Fifteen of 21 patients responded to treatment. Of 254
FLs analysed, sFF (p < 0.0001) and ADC (p = 0.001) signifi-
cantly increased in responders but not non-responders. eTV
significantly decreased in 19/21 cases. Focal lesion sFF was
the best discriminator of treatment response (AUC 1.0). Bone
sFF repeatability was excellent (ICC 0.98) and better than
bone ADC (ICC 0.47).
Conclusion WB-MRI derived focal lesion sFF shows promise
as an imaging biomarker of treatment response in newly diag-
nosed MM.
Key Points
• Bone signal fat fraction using mDixon is a robust quantifi-
able parameter
• Fat fraction and ADC significantly increase in myeloma
lesions responding to treatment
• Bone lesion fat fraction is the best discriminator of myeloma
treatment response
Keywords MRI .Whole body .Multiple myeloma .
Bortezomib . Responsemonitoring
Introduction
Multiple myeloma (MM) is a heterogeneous disease where
tumour deposits occur commonly within the bone marrow
(BM) of the axial and appendicular skeletons.
Over the past decade whole-body MRI (WB-MRI) has
developed as a newmodality for cancer detection. Inmyeloma
WB-MRI is superior to skeletal survey, computed
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tomography, positron emission tomography and whole spine
MRI for pretreatment assessment [1–4]. The International
Myeloma Working Group (IMWG) consensus guidelines
and the National Institute of Care and Health Excellence
(NICE) have recommended WB-MRI as the imaging modal-
ity of choice for pretreatment assessment of plasma cell disor-
ders [5, 6].
Despite availability of imaging methods for staging dis-
ease, treatment response in myeloma is assessed using global
indirect measures including serum and urine M-protein levels,
serum free light chain ratio and percentage of clonal plasma
cells in bone marrow biopsy [7].
Anatomical MRI sequences depict the pattern of BM in-
volvement and characterise the number/size of focal lesions,
providing diagnostic/prognostic information in MM [8, 9].
Change in disease pattern/visualization following treatment
on anatomical MRI has some value in monitoring response,
but remains subjective and inconsistent [9, 10]. Addition of
functional imaging biomarkers [11, 12] may provide quanti-
tative monitoring of treatment response and potentially indi-
cate outcome at early stages of treatment [13]. Indeed, quan-
titative measurements from dynamic contrast-enhanced
(DCE) and diffusion-weighted (DWI) MR imaging show
promising results for disease characterization and response
monitoring in MM [14–17].
However, there is as yet no agreed methodology for
imaging-based quantitative evaluation of treatment response
in MM; moreover, repeatability of currently proposed bio-
markers remains challenging. There remains a need to define
a reliable, sensitive and specific biomarker that can be used for
whole-body imaging, providing an assessment of heterogene-
ity of treatment response across skeletal lesions.
The purpose of this study was to evaluate WB-MRI quan-
titative biomarkers of treatment response for patients with
symptomatic MM.
Methods
A prospective single-arm observational study was conducted.
Institutional ethics permission was obtained (REC Number:
12/LO/0428). Participants were recruited from a single tertiary
centre and gave written informed consent.
Patient cohort
Thirty patients were prospectively identified from multidisci-
plinary team meetings (consisting of a radiologist, pathologist
and haematologist) between June 2012 and September 2014
inclusive (M/F 13:17, median age 55, range 36–82 years).
Inclusion criteria were age at least 18 years; clinical suspicion
of symptomatic MM; no previous malignancy, chemotherapy
or radiotherapy; eGFR greater than 50 mL/min/1.73 m2; no
contraindication to MRI.
Prior to chemotherapy, all patients (n = 30) underwent
baseline WB-MRI. Symptomatic MM patients (n = 26) were
treated with 4–8 cycles of bortezomib-based chemotherapy
and repeatWB-MRI performed at the end of the second cycle.
Treatment response was evaluated by the clinical team,
blinded to imaging results, on the basis of International
Myeloma Working Group consensus after bortezomib induc-
tion [7] and patients classified into ‘responder’ and ‘non-re-
sponder’ groups based on achieving a minimum of partial
response.
All non-responders were escalated to salvage chemothera-
py treatment with bortezomib, thalidomide and dexametha-
sone (VTD) whilst responding patients went on to have im-
mediate (n = 7) or deferred (n = 8 as part of the PADIMAC
trial: EudraCT 2010-021598-35) autologous stem cell
transplant.
Figure 1 presents the patient selection flowchart.
Volunteer cohort
Repeatability of WB-MRI quantitative metrics was assessed,
by repeating WB-MRI at a median of 4 weeks (range 1–11
weeks) between 1st and 2nd scans, in 10 healthy volunteers
(M/F 6:4, median age 33 years, range 24–39 years) recruited
from our institutional employees between January 2013 and
October 2014.
WB-MRI technique
Imaging was performed using a single 3.0-T wide-bore MR
scanner (Ingenia; Phillips Healthcare, Best, Netherlands). Full
body coverage (vertex to feet) was obtained through a
multistation acquisition of contiguous body regions with the
manufacturers’ head coil, two anterior surface coils and table-
embedded posterior coils. Whole-body coronal pre-contrast
mDixon imaging was complemented by axial T2-weighted
turbo spin echo (TSE), axial DWI (with four b values,
b0,100,300 and 1000) and finally, coronal contrast-enhanced
(CE) mDixon imaging. CE MRI was performed following
20 ml of intravenous (IV) gadoterate meglumine (Dotarem,
Guebert, France) injection. The average total scan time was
67 min. For mDixon imaging a 3D gradient echo sequence
with two echoes acquired at first out-of-phase and first in-
phase time of echoes was used, to maximise signal-to-noise
ratio and minimise effect of T2* decay. Post-processing of
attained out-of-phase and in-phase images using scanner soft-
ware created fat-only and water-only images. The same pro-
cedure was repeated following contrast agent injection (CE
mDixon).
5326 Eur Radiol (2017) 27:5325–5336
CE mDixon was not performed in the volunteer cohort as
the majority of participants did not consent to IV contrast
injection.
Full scanning parameters are summarised in Table 1.
WB-MRI quantitative analysis
Patient cohort
Two radiologists (MHC and SP with over 25 and 10 years of
experience in MR imaging, respectively) reviewed images in
consensus and blinded to other investigations. The pattern of
BM involvement was noted for each patient using a combina-
tion of all available sequences as previously reported [18].
FLs in 10 contiguous anatomical locations (skull, cervical
spine, shoulder girdle, humerus, chest wall, thoracic spine,
lumbar spine, pelvis, femur and lower leg) were localized on
WB-DWI and CE water-only mDixon MRI.
FLs were identified as focal areas of restricted diffusion
returning high signal intensity on DWI b1000 images and in-
creased contrast uptake on CE water-only mDixon images
compared to surrounding marrow. A 5-point scale was used
to score confidence of lesion presence (0, non-diagnostic; 1,
unlikely; 2, indeterminate; 3, likely; and 4, highly likely
disease).
As a result of the heterogeneous nature of MM and its
tendency to involve the entire skeleton, and in order to provide
a practical and comparable global measure of disease across
bony sites, a maximum of 20 FLs per patient were selected on
the basis of the following applied rules:
I. Included only lesions of at least 5 mm, scored 3/4 and
visible on anatomically matched b1000 DWI and CE
water-only mDixon
II. Included all lesions from anatomical locations with less
than three lesions
III. Included largest lesions from other sites, to a make up for
a maximum of 20 FLs per patient based on current
Durie–Salmon PLUS staging criteria [19]
Biomarker quantitation
Analysis was performed using Osirix (Version 4.0, Apple,
California, USA).
For quantitative analysis, a single slice containing the FL’s
largest dimension was indicated by two reporting radiologists
(MHC and SP) in consensus who derived the quantitative
parameters as below.
Fig. 1 Patient selection and recruitment flowchart
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Estimated tumour volume (eTV) (cm3): Individual lesion
volume was calculated from three-axis measurements on CE
water-only mDixon (X/Y) and b1000 DWI (Z) images; eTVwas
calculated as (X × Y × Z/2).
Enhancement ratio (ER) (%): Average signal intensity (SI)
was measured for lesions on pre- and post-CE water-only
mDixon images and ER calculated as [(SI post-contrast-W − SI
pre-contrast-W)/SI pre-contrast-W] × 100.
Apparent diffusion coefficient (ADC) (×10−3 mm2/s):
Average signal intensity of lesions was derived for each b
value. ADC was derived using a mono-exponential curve fit
imp lemen ted in MATLAB 2011a (Ma thWorks ,
Massachusetts, USA) [20].
Signal fat fraction (sFF) (a.u.): sFF was derived from av-
erage signal intensity of on pre-contrast water and fat-only
mDixon images. sFF = SI pre-contrast-F/(SI pre-contrast-F + SI pre-
contrast-W) [21].
Finally, and as an internal control within the patient cohort,
the sFF of the greater trochanter (involved uncommonly by
myeloma) was calculated at each time point using a 3 cm2
region of interest (ROI).
Volunteer cohort
sFF and ADC repeatability was assessed on matched coronal
mDixon and ADC maps by a single observer. For each vol-
unteer, seven single slice skeletal ROIs (T10 and L4 vertebral
bodies, sacroiliac joint and sacral ala, iliac crest, femoral head
and neck, mid-shaft femur and distal femur), a 2 cm3 circular
ROI of the spleen on ADC maps and a 3 cm3 circular ROI of
subcutaneous adipose tissue at the level of right femoral great-
er trochanter on mDixon MRI images were measured at two
time points using Osirix (Version 4.0, Apple, California,
USA).
Statistical analysis
Grouped analysis
Distribution normality was assessed by the Kolmogorov–
Smirnov test. Mean lesion values of MRI biomarkers (eTV,
ER, ADC and sFF) were derived for both groups, for baseline
and post-2nd cycle scans. Changes of MRI biomarkers be-
tween baseline and post-2nd cycle scans were assessed for
each group by the two-tailed paired t test.
The two-tailed Mann–Whitney test was used to compare
lesion count between responder and non-responder groups.
Statistically significant differences were defined as p < 0.05.
Per patient analysis
Median lesion values of MRI biomarkers across all selected
FLs were derived for each individual patient for baseline and
early post-treatment studies. Changes of MRI biomarkers be-
tween the two time points were assessed for each patient by
the two-tailed Wilcoxon matched-pairs signed-rank test.
Statistically significant differences were defined as p < 0.05.
Table 1 MRI sequence
parameters T2-TSE mDixon (pre and post-
contrast*)
DWI (b0, 100,
300, 1000)
Imaging plane Transverse Coronal Transverse
TE (ms) 80 1.02/1.8 71
TR (ms) 1228 3.0 6371
FOV (mm×mm) 500 × 300 502 × 300 500 × 306
Voxel size (mm ×mm) 1 × 1 2.1 × 2.1 4 × 4.2
Number of slices 40 120 40
Slice thickness (mm) 5 5 5
Acquisition matrix 500 × 286 144 × 238 124 × 72
ETL 91 2 39
Acceleration factor
(SENSE)
2 2 2.5
Pixel bandwidth (Hz) 537 1992 3369
Acquisition time per
station (s)
47 17 152
Number of stations 9 5 (6) 9
Total FH coverage
(mm×mm)
1777.95 (10% overlap) 1736 (10% overlap) 1777.95 (10% overlap)
T2-TSE T2-weighted turbo spin echo, mDixon modified Dixon, DWI diffusion weighted imaging, TE time of
echo, TR time of repetition, ETL echo train length, SENSE sensitivity encoding
*Contrast agent 20 ml intravenous gadoterate meglumine (Dotarem, Guerbet, France)
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Receiver operating characteristics (ROC) curves, for pre-
diction of non-responding patients, were derived for eachMRI
biomarker at each time point, and for percentage change in
each MRI biomarker following treatment ([early post-treat-
ment − baseline] × 100/baseline). The area under the curve
(AUC) was quantified to assess performance for discriminat-
ing non-responding patients across all possible diagnostic
thresholds.
Biomarker repeatability (volunteer cohort)
Repeatability of sFF and ADC of bone, ADC of spleen and
sFF of subcutaneous adipose tissue was assessed by one-way
random single measure interclass correlation coefficient (ICC)
statistics and Bland–Altman plots.
Statistical analysis was performed using Prism software
(Prism Version 6.0, GraphPad, California, USA) by the study
clinical research fellow (AL).
Results
Patient cohort
Four patients (4/30) did not have symptomatic MM and were
excluded (one monoclonal gammopathy of uncertain signifi-
cance, one asymptomatic multiple myeloma, two solitary
plasmacytoma).
Three patients (3/26) did not have the second scan because
of interval surgery or patient preference. Two further patients
with post-2nd cycle scans were excluded from quantitative
analysis as one underwent radiotherapy and a second had no
FL. MRI biomarkers were evaluated in the remaining 21
patients.
Demographics, blood tests, staging and treatment regimens
for 21 patients are summarised in Table 2.
Fourteen (14/21) patients had focal only and seven (7/21)
patients diffuse and focal pattern of involvement. Fifteen of 21
patients achieved a minimum of partial response (PR) after
induction chemotherapy [3/15 with PR, 3/15 with complete
response (CR) and 9/15 with very good partial response
(VGPR)] and were collectively classified as the responder
group. Six of 21 patients achieved less than PR (<PR) to
induction chemotherapy [4/6 with minimal response (MR),
1/6 with stable disease (SD) and 1/6 with progressive disease
(Prog)] and were collectively classified as non-responders.
Grouped analysis
The median number of lesions evaluated per patient was 14
(range 1–18). A total of 186 (median 14, range 1–18) and 68
(median 12, range 7–15) FLs were evaluated in responder and
non-responder groups respectively (p = 0.33).
Mean [standard deviation (SD)] eTV, ADC, sFF and ER at
baseline and post-2nd cycle for responders and non-
responders is shown in Table 3.
Following treatment, there was a significant reduction in
eTV in responding groups (p < 0.02) whilst no significant
changes were observed in non-responder group (p = 0.09).
sFF increased significantly for the responder group
(p < 0.0001), but not for the non-responder group (p = 0.21).
Similarly, ADC significantly increased in responders (p =
0.001) but not in non-responders (p = 0.15). No significant
change was observed for ER for either group (p = 0.99 and
0.48 for responders and non-responders, respectively). Group-
based analysis for temporal changes of each biomarker is pre-
sented in Fig. 2.
Per patient analysis
One (1/15) responder patient had a single FL and was there-
fore excluded from per patient analysis. An example of an FL
at baseline and post-2nd cycle in a responding patient is pre-
sented in Fig. 3.
Table 2 Patient cohort: demographics, routine blood tests, staging and
chemotherapy regimen
Patient characteristic (N = 21) Number or median (range)
Age 55 (36–69)
Sex Male/female: 13/8
Chain isotype
IgG 14
IgA 4
Light chain 3
ISS stage
I 6
II 12
III 3
DS-PLUS stage
I 1
II 2
III 18
Induction regimen
PAD 16
CVD 3
VTD 2
Bone marrow percentage plasma cells 65 (15–90)
Beta-2 microglobulin (mg/L) 3.8 (1.3–10.3)
Albumin (g/L) 40 (32–53)
Creatinine (μmol/L) 79 (58–105)
ISS international staging system, DS-PLUS Durie–Salmon PLUS, PAD
bortezomib, doxorubicin, dexamethasone, CVD cyclophosphamide,
bortezomib, dexamethasone, VTD bortezomib, thalidomide,
dexamethasone
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Following treatment, there was a significant increase in sFF
for 13/14 responders (p < 0.01 to 0.03). For the remaining
patient (1/14) with four FLs the change in sFF did not reach
statistical significance (median sFF 0.27 and 0.36 a.u. at
Fig. 2 Box and whisker plots of temporal changes of a signal fat fraction
(sFF), b apparent diffusion coefficient (ADC), c estimated tumour
volume (eTV) and d enhancement ratio (ER) in responder and non-
responder groups. The boundaries of the box show 25th and 75th
percentiles, and the line within the box is the median. Whiskers show
10th and 90th percentiles. Means (+) and outliers (•) are shown. Each
point represents a patient
Table 3 Patient cohort: mean and
standard deviation of imaging
biomarker distribution at baseline
and post-2nd cycle in responder
and non-responder groups
Scan Mean eTV
(SD)
Mean ER
(SD)
Mean ADC
(SD)
Mean sFF
(SD)
Responders
(n = 15)
Baseline 0.41 (0.36) 142 (101.40) 0.89 (0.32) 0.28 (0.11)
Post-2nd cycle 0.28 (0.30) a 142 (67.30) 1.34 (0.49) a 0.52 (0.16) a
Non-responders
(n = 6)
Baseline 0.52 (0.53) 107.5 (41.77) 0.59 (0.15) 0.40 (0.14)
Post-2nd cycle 0.29 (0.28) 131.5 (72.46) 0.78 (0.41) 0.43 (0.17)
eTV estimated total tumour volume, ER enhancement ratio, ADC apparent diffusion coefficient, sFF signal fat
fraction, SD standard deviation
a Significant change (p < 0.05) compared with baseline scan
5330 Eur Radiol (2017) 27:5325–5336
baseline and post-2nd cycle respectively, p = 0.12). There was
no significant change in sFF following treatment in any of the
six non-responder patients (p = 0.30 to 0.60).
ADC increased significantly following treatment in 7/14
responders (p < 0.01 to 0.04.). Six of 14 responders demon-
strated no significant change of ADC (p = 0.12 to 1.0); and 1/
14 demonstrated a significant decrease in ADC (median ADC
of 1.08 and 0.68 × 10−3 mm2/s at baseline and post-2nd cycle,
respectively, p = 0.01).
In the non-responder group, ADC did not change signifi-
cantly following treatment in 4/6 patients (p = 0.50 to 0.97),
and increased in 2/6 (p = 0.02 and 0.03).
The eTV decreased significantly in all six non-responders
(p < 0.01 to 0.01) and in 13/14 responding patients (p < 0.01
to 0.02) with no significant change in the patient with four FLs
(p = 0.62).
In 6/14 responders, there was no significant change of ER
following treatment (p = 0.20 to 0.93). The ER decreased sig-
nificantly in 2/14 (p < 0.01) and significantly increased in 6/14
(p < 0.01 to 0.03). There was no significant change of ER in 3/
6 (p = 0.14 to 0.31), and a significant increase of ER in 3/6
(p = 0.01 to 0.05) non-responder patients following treatment.
Changes in sFF, ADC, eTV and ER for lesions in typical
responder and non-responder patients are provided in Figs. 4
and 5, respectively.
Two patients (2/21) were excluded from analysis of the
trochanteric sFF because of tumour involvement or artefact.
There were no significant changes of sFF in normal-appearing
greater trochanter (n = 19) following therapy (mean [standard
deviation] of 0.97 [0.007] and 0.97 [0.007] at baseline and
post-treatment, respectively, p = 0.16).
ROC curves
The ROC curve analyses for eTV, ER, sFF and ADC using
baseline, early post-treatment and percentage change follow-
ing treatment as predictors of non-responding patients and
AUC values are tabulated in Table 4. ROC analysis indicated
that a threshold of 12.6% increase in sFF correctly identified
response to treatment with 100% sensitivity and 100% speci-
ficity (AUC, 1.0).
Biomarker repeatability (volunteer cohort)
Median and interquartile ranges (IQR) of bone, splenic and
subcutaneous adipose tissues ROIs for the first and second
studies and ICC (95% confidence interval) between temporal-
ly separated studies are shown in Table 5. The ICC of sFF and
ADC of normal bone were 0.98 (95% CI 0.96–0.98) and 0.47
Fig. 3 Representative images of the whole-body MRI scan of a 52-year-
old female participant prior to (a1–c1) and following two cycles (a2–
c2) of induction PAD (bortezomib, doxorubicin, dexamethasone)
chemotherapy. a1, a2 coronal signal fat fraction map; b1, b2 coronal
post-contrast water-only mDixon; c1, c2 Axial b1000 diffusion-weighted
MRI images depicting a focal lesion at the level of L3 vertebral body on
the right side (arrows). Compared to baseline and following two cycles of
treatment there were a 42.7% reduction in eTV, 51.7% reduction in ER,
25% increase in ADC and 80% increase in FF of the focal lesion
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(95% CI 0.26–0.63) respectively. The Bland–Altman plots for
bone sFF and ADC measurements are presented in Fig. 6.
Discussion
WB-MRI is increasingly used for initial evaluation of patients
with MM. Recently, qualitative and quantitative assessments
of WB-MRI have yielded promising results for monitoring
response in MM [9, 13, 14].
Our study demonstrates that MR-derived sFF is a reliable
and quantifiable technique and that its changes following two
chemotherapy cycles were a consistent and accurate classifier
of treatment response.
Our findings on WB-MRI confirm previous reports on re-
peatability and reproducibility of sFF of lumbar spine [22] and
subcutaneous adipose tissue [23].
We observed a significant increase in sFF in responders
(13/14) compared to no significant change in non-responders
(6/6).
Few studies have investigated sFF quantification of bone
marrow in MM. Takasu et al. [24] demonstrated a significant
decrease in lumbar spine fat fraction of 24 MM patients, com-
pared to healthy volunteers, monoclonal gammopathy of un-
determined significance and asymptomatic MM patients,
using iterative decomposition of water and fat with echo
asymmetric and least-squares estimation (IDEAL) [25] MRI.
In their cohort, discriminant analysis of sFF showed that 92%
of patients were classified correctly into symptomatic or non-
symptomatic MM groups.
FLs’ response sometimes does not reflect as a change in
lesion diameter, but rather progressive fading of the marrow
abnormalities and return to normal marrow signal intensity
within the lesion [26] as reflected in our results.
Although we found a significant increase of ADC in our
responder group we observed more variation in per patient
analysis than reported previously on 1.5-T DW MR imaging
[13, 15]. The temporal changes of ADC following myeloma-
tous infiltration and treatment are complex and affected by
several factors such as the amount of fatty (yellow) marrow,
cell size, bulk flow in capillaries and cellular architecture [27].
Furthermore, the direction and magnitude of ADC changes
may depend on the stage of bone remodelling cycle captured
in individual patients, and individual lesions.
Fig. 4 Per patient changes of
signal fat fraction (sFF), apparent
diffusion coefficient (ADC),
estimated tumour volume (eTV)
and enhancement ratio (ER)
between baseline and post-2nd
cycle scans. Subject is a 46-year-
old male participant who
achieved complete response (CR)
after induction chemotherapy
with PAD (bortezomib,
doxorubicin, dexamethasone).
Each data point is representative
of a focal lesion at baseline and
post-2nd cycle scan. Significant
defined as p < 0.05
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We observed a significant decrease in eTV following treat-
ment in almost all the patients (19/20) but found no significant
change in FL enhancement following treatment, concurring
with a previous report [14].
Persistent increased angiogenesis previously reported in
MM following successful treatment might explain observed
ER changes in our cohort [28]. Furthermore, perceived chang-
es in eTV could highlight inadequacy of single axis size mea-
surement in FLs as a measure of response/progression.
A prerequisite of a successful response biomarker, in addi-
tion to changing with treatment, is clinically acceptable re-
peatability. We determined the repeatability of bone ADC
and sFF measurements in normal volunteers, and showed that
sFF has excellent repeatability (ICC of 0.98) compared with
moderate repeatability of ADC (ICC bone 0.47). A separate
splenic ROI was used as DWI is normally performed with fat-
suppression which may reduce the signal-to-noise ratio on
DWI images in normal marrow and affect ADC calculation
and thus repeatability. In the spleen (where DWI signal is
high) ADC has good repeatability.
The repeatability of sFF measurements, its modifiability
with treatment together with the significant increase with suc-
cessful treatment, strongly supports the use of sFF as a bio-
marker of treatment response in patients with MM.
Fig. 5 Per patient changes of
signal fat fraction (sFF), apparent
diffusion coefficient (ADC),
estimated tumour volume (eTV)
and enhancement ratio (ER)
between baseline and post-2nd
cycle scans. Subject is a 55-year-
old male participant who
achieved minimal response (MR)
after induction chemotherapy
with PAD (bortezomib,
doxorubicin, dexamethasone).
Each data point is representative
of a focal lesion at baseline and
post-2nd cycle scan. Significant
defined as p < 0.05
Table 4 Patient cohort: univariate area under the curve (AUC) analysis
of the imaging biomarkers at baseline, post-2nd cycle and their respective
percentage changes
AUC Std. Asymptomatic 95% CI
Lower bound Upper bound
Baseline eTV 0.55 0.15 0.26 0.84
ER 0.48 0.13 0.23 0.72
ADC 0.78 0.10 0.58 0.98
sFF 0.78 0.11 0.56 1.00
Post-2nd cycle eTV 0.56 0.15 0.26 0.86
ER 0.51 0.13 0.26 0.76
ADC 0.80 0.10 0.61 0.99
sFF 0.73 0.12 0.49 0.97
Percentage changes eTV 0.42 0.13 0.16 0.69
ER 0.48 0.13 0.22 0.74
ADC 0.70 0.13 0.44 0.96
sFF 1.00 0.00 1.00 1.00
eTV estimated tumour volume, ER enhancement ratio, ADC apparent
diffusion coefficient, sFF signal fat fraction, AUC area under the curve,
Std standard deviation
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Our study has some limitations. Although we observed
differential responses between lesions within individual pa-
tients, we could not confirm response on a per lesion basis,
as our reference standard was defined by a global patient-
based response. It is possible that individual lesions that do
not appear to be responding, in accordance with our observed
MRI biomarker change associated with global response, are
the sites of resistance to therapy. Further temporal follow-up
with and without individual lesion biopsy is necessary to ex-
plore this hypothesis.
Because the focal pattern constitutes the most common
pattern of bone marrow involvement in MM [29], as reflected
in our cohort, our findingsmay not be generalizable to patients
with diffuse-only pattern of disease.
Additionally, the second time point (post-2nd cycle) was an
arbitrary choice in our study as there is currently no consensus
on the optimal point for early/late follow-up imaging in MM
using WB-MRI.
We acknowledge that changes as early as 1-month post
chemotherapy have been documented for ADC in MM pa-
tients [21] however, the most optimal post-treatment interval
with greatest sensitivity to separate responders and non-
responders patients is yet to be confirmed.
As we required whole-body coverage, we were limited to
static CEMRI following a constant administration of 20 ml of
gadolinium as opposed to dynamic CE MR imaging. In static
CE MRI, the final gadolinium concentration at equilibrium
state is measured, which provides less discriminative informa-
tion than dynamic CE (DCE) imaging, as previously reported
when applied to the spine for prognostic categorization of
MM patients [30].
Finally, we used our volunteer cohort to assess quantitative
parameter repeatability, and we acknowledge that our volun-
teer cohort was not sex- and age-matched to the patient cohort.
Our observations require subsequent confirmation in a
larger patient cohort. Imaging was performed on a single
MRI scanner and so biomarker generalizability between plat-
forms and institutions/settings is untested. However, the pulse
sequences used are routinely available on all commercially
available scanners, quantification is relatively simple, and re-
peatability of sFF (our best response biomarker) is almost
perfect.
We envisage that a 10-min WB-MRI mDixon imaging
could provide a safe, fast and cost-effective technique with
simple and reliable quantification of sFF to assess treatment
response accurately, and has the potential to aid treatment
Fig. 6 Bland–Altman plots of signal fat fraction (sFF) and apparent
diffusion coefficient (ADC). For sFF, 95% limits of agreement were
−0.085 to 0.105 (a.u.) with standard of bias of 0.048. For ADC, 95%
limits of agreement were −134.3 to 162.1 (mm2/s × 10−6) with standard of
bias of 75.61. There is a wider dispersion of values for ADC and mean
differences between two measurements in each subject are closer to zero
for sFF compared to ADC. The dotted lines represent 95% level of
agreement
Table 5 Biomarker repeatability of normal volunteer cohort: median and interquartile range (IQR) of apparent diffusion coefficient and signal fat
fraction of bone, apparent diffusion coefficient of spleen and signal fat fraction of subcutaneous adipose tissue for two scans and interclass correlation
(ICC) and 95% confidence interval results are summarized
Bone Spleen Adipose tissue
ADC sFF ADC sFF
1st scan 0.31 (0.28–0.36) 0.74 (0.55–0.93) 0.75 (0.74–0.79) 0.95 (0.93–0.96)
2nd scan 0.31 (0.26–0.35) 0.70 (0.56–0.94) 0.77 (0.75–0.80) 0.94 (0.93–0.96)
ICC (95% CI) 0.47 (0.26–0.63) 0.98 (0.96–0.98) 0.83 (0.47–0.95) 0.93 (0.75–0.98)
ADC apparent diffusion coefficient, sFF signal fat fraction, ICC interclass correlation, CI confidence interval
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stratification by early identification of poorly responding pa-
tients. Moreover, sFF imaging may demonstrate heterogeneity
of lesion response, which, if verified, may identify lesions
containing resistant disease, facilitating targeted biopsy and
guiding further therapy. Evolving risk stratification methods
are integrating more advanced and sophisticated tests (e.g.
cytogenetic analysis) for assessment of MM and WB-MRI
sFF could potentially provide added value in making clinical
management decisions within this heterogeneous disease.
In conclusion, we found that WB-MRI sFF assessment
using a simple MRI technique provides a reliable MRI bio-
marker for assessing therapeutic response and potentially dis-
criminates clinical outcome in patients with symptomatic mul-
tiple myeloma.
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